Jesse’s Journey Becomes Defeat Duchenne Canada
New Name – Same Mission: Jesse’s Journey Becomes Defeat Duchenne Canada
Jesse’s Journey, Canada’s only national charity dedicated to ending the most common and most fatal form of muscular dystrophy has become Defeat Duchenne Canada. The London-based organization has united families, raised awareness and funded almost $15 million in research projects around the world. After more than 30 years under the banner of Jesse’s Journey, Canada’s leading fundraiser for Duchenne muscular dystrophy has partnered with its vibrant community members to choose a new name that reflects their nationwide impact.
Read the full press release from Defeat Duchenne Canada here.
About Defeat Duchenne Canada
Defeat Duchenne Canada is the country’s only national charity dedicated to ending Duchenne muscular dystrophy.
Their goal is to provide leadership in research, advocacy and support to ensure our boys can live long and active lives.
The NMD4C are excited to continue our partnership with Defeat Duchenne Canada, and are grateful to have the opportunity to work together to raise the standards of care for NMDs and access to therapies across Canada.
Check out the three-part Defeat Duchenne Canadian Conference Series addressing Duchenne Muscular Dystrophy Standards of Care in Canada, hosted in 2021 by Defeat Duchenne Canada in collaboration with MDC and the NMD4C.
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.